Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.

Nyxoah is entering its first growth stage, targeting the OSA device market with the Genio implant, and is currently undervalued relative to growth prospects. Genio could secure a monopoly on 30% of the OSA market by 2027, pending FDA label extension for Complete Concentric Collapse (CCC) patients, supported by strong clinical trial results. NYXH projects €36 million revenue for 2026, up 260% YoY, with visibility supported by rapid growth in trained surgeons, active accounts, and prior authorizations.